Last reviewed · How we verify
ASTX727 Dose Escalation
At a glance
| Generic name | ASTX727 Dose Escalation |
|---|---|
| Also known as | cedazuridine (E7727), oral decitabine, IV decitabine |
| Sponsor | Astex Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (PHASE1)
- Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors (PHASE1)
- Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (PHASE1)
- Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes (PHASE1)
- Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASTX727 Dose Escalation CI brief — competitive landscape report
- ASTX727 Dose Escalation updates RSS · CI watch RSS
- Astex Pharmaceuticals, Inc. portfolio CI